Alignment Healthcare LLC (ALHC)
Official siteHEALTHCARE • HEALTHCARE PLANS • NASDAQ
Market Cap: $1.54B
Last updated: Nov 17, 2026 at 11:04 AM ET
Alignment Healthcare LLC (ALHC) Stock Forecast
Analysts expect Alignment Healthcare LLC (ALHC) to earn $0.27 per share in the fiscal year ending Dec 31, 2026, on revenue of $5.26B. Of 15 analysts, 9 rate the stock Buy or Strong Buy, 6 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.20, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 60% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 20.0% |
| Buy | 6 | 40.0% |
| Hold | 6 | 40.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 107.4% and revenue estimates rise 24.9%.
- Fiscal year ending Dec 31, 2026
- $0.27
- EPS consensus, revenue $5.26B
- Fiscal year ending Dec 31, 2027
- $0.56
- EPS consensus, revenue $6.57B
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.27 | $0.24 to $0.29 | 4 | $5.26B | $5.25B to $5.31B | 11 |
| Dec 31, 2027 | $0.56 | $0.45 to $0.69 | 4 | $6.57B | $6.42B to $6.75B | 13 |
Quarterly Estimates
The EPS consensus rises from -$0.20 for the quarter ending Dec 31, 2026 to $0.15 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.20 | -$0.29 to -$0.01 | 17 | $1.36B | $1.29B to $1.45B | 15 |
| Mar 31, 2027 | $0.15 | $0.13 to $0.16 | 3 | $1.56B | $1.53B to $1.61B | 8 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 4 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 46.0% from $0.50.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.27 | $0.45 | $0.50 | $0.50 | $0.50 | -46.5% |
| Fiscal year ending Dec 31, 2027 | $0.56 | $0.65 | $0.75 | $0.75 | $0.75 | -26.2% |
| Quarter ending Mar 31, 2027 | $0.15 | $0.19 | $0.19 | $0.19 | $0.19 | -24.1% |
Frequently Asked Questions About ALHC
What is the ALHC stock forecast?
Consensus analyst estimates put Alignment Healthcare LLC's EPS at $0.27 for the fiscal year ending Dec 31, 2026, on revenue of $5.26B. The consensus rating from 15 analysts is Buy.
How do analysts rate ALHC stock?
Of 15 analysts covering Alignment Healthcare LLC, 3 rate it Strong Buy, 6 Buy, 6 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ALHC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.27, with estimates from $0.24 to $0.29 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.56, with estimates from $0.45 to $0.69 from 4 analysts.
What revenue do analysts expect from Alignment Healthcare LLC next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $5.26B, with estimates from $5.25B to $5.31B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.57B, with estimates from $6.42B to $6.75B.
How many analysts cover ALHC?
15 analysts rate Alignment Healthcare LLC stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ALHC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors